DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that its affiliate, FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled (PET) tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.
